Xintela AB (1XT) AI Stock Analysis

Xintela AB

(Frankfurt:1XT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused ITGA10 platformA focused platform around ITGA10 gives Xintela a coherent scientific identity across two medical applications. Reusing the same receptor expertise in cell therapies and antibodies may improve research leverage and create multiple routes to commercial value over the next several quarters.

Negative Factors

Severe and persistent lossesThe scale of losses relative to revenue shows that the current operating structure is far from self-sustaining. Persistent negative EBIT, EBITDA, and net income reduce internal funding capacity and mean that meaningful progress depends on future revenue growth, partnering proceeds, or additional financing.

Xintela AB (1XT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 12.20M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.7
Beta (1Y): 0.56
Revenue Growth: -36.04%
EPS Growth: 5.26%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XIN...

Xintela AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1XT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:XBRANE	53Neutral	SEK 291.57M	-5.90	-13.41%	―	-38.80%	-120.18%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ISOFOL	49Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:NXTCL	46Neutral	SEK 29.07M	-0.60	-81.23%	―	-4.02%	35.86%
SE:ACTI	42Neutral	SEK 105.31M	-10.14	-93.01%	―	―	54.60%

* Healthcare Sector Average

Performance Comparison

DE:1XT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1XT	Xintela AB	0.01	-0.02	-66.67%
SE:XBRANE	Xbrane Biopharma AB	14.15	3.35	31.02%
SE:ISOFOL	Isofol Medical AB	1.20	0.51	74.89%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:ACTI	Active Biotech AB	4.00	-2.42	-37.76%
SE:NXTCL	NextCell Pharma AB	0.23	-0.66	-74.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Xintela AB AI Stock Analysis